Analisi di impatto sul budget di differenti analoghi ad azione rapida dell’insulina in Italia
Introduction: Rapid-acting insulins are the current standard of care in diabetes management. Insulin aspart (IA), lispro (IL) and glulisine (IG) demonstrated similar efficacy and safety. However, their impact on the National Health Service (NHS) expenditure could be a relevant differentiating factor...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2018-03-01
|
| Series: | Global & Regional Health Technology Assessment |
| Online Access: | https://doi.org/10.1177/2284240318759418 |